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Abstract. Several neurological disorders such as stroke,
amyotrophic lateral sclerosis and epilepsy result from 
excitotoxic events and are accompanied by neuronal cell
death. These processes engage multiple signalling path-
ways and recruit numerous molecular components, in 
particular several families of protein kinases and protein
phosphatases. While many investigations have examined
the importance of protein kinases in excitotoxicity, protein
phosphatases have not been well studied in this context.
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However, recent advances in understanding the functions
of protein phosphatases have suggested that they may play
a neuroprotective role. In this review, we summarize some
of the recent findings that illustrate the pleiotropic and
complex functions of tyrosine and serine/threonine pro-
tein phosphatases in the cascade of events leading to neu-
ronal cell death, and highlight their potential intervention
in limiting the extent of neuronal death.
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Introduction
Neurological and cognitive disorders associated with de-
generation of brain tissue represent a major challenge for
clinicians and research scientists because of the limited
potential for de novo production of nerve cells in the ma-
ture organism. Although the mechanisms of degeneration
and death of brain cells are not fully understood, one of
their features appears to be linked to aberrant phosphor-
ylation of proteins in these cells. Abnormal phosphoryla-
tion has been associated with excitotoxicity, a process
that generally results from the excessive stimulation of
calcium-permeable glutamate receptors followed by mas-
sive calcium influx into cells, inappropriate activation of
calcium-dependent enzymes, production of free radicals,
alteration of mitochondrial functions and ultimately initi-
ation of cell death. Neuronal loss due to excitotoxicity
may contribute to the pathophysiology of chronic neu-
rodegenerative illnesses such as Alzheimer’s disease,
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amyotrophic lateral sclerosis, Parkinson’s disease and
Huntington’s disease [1–4].
Clearly, multiple pathways are affected in response to
perturbed calcium homeostasis. This represents a major
complication for the development of potential therapeutic
intervention. For instance, interfering with one of the
most upstream molecular components of the cascade
such as glutamate receptors in an attempt to hinder the
whole cascade has proven unsuccessful. The develop-
ment of specific antagonists acting on neuronal gluta-
mate receptors has not provided the expected beneficial
effect for treatment because of the multiplicity and sever-
ity of their side effects. Advances in the identification and
understanding of pathways implicated in excitotoxicity
and neuronal cell death have, however, raised the hope
that targeting intracellular transduction elements down-
stream from glutamate receptors may prove a useful
strategy for alleviating or attenuating neuronal injury. Of
particular interest in this respect are protein phos-
phatases, which despite their demonstrated implication
in excitotoxicity may play an important role in the mech-
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anisms that limit brain damage and mediate neuropro-
tection. In this review, we summarize recent findings
suggesting the involvement of tyrosine and serine/threo-
nine protein phosphatases in neuroprotection, with a fo-
cus on experimental findings derived from models of
brain injury such as transient or global cerebral ischemia,
glutamate excitotoxicity and hypoxia. We try to illustrate
the pleiotropic functions and complexity of the mecha-
nisms that these molecules are involved in during these
processes (see table 1).
Tyrosine and serine/threonine protein phosphatases
Tyrosine and serine/threonine protein phosphatases are
highly abundant proteins present in many cellular com-
partments of mammalian cells. Together with protein 
kinases, they set the phosphorylation state of signalling
and effector proteins and thereby play a large role in con-
trolling cellular responses. The balance between protein
phosphatases and kinases is essential for the regulation of
cellular signalling, and inappropriate or defective phos-
phatase or kinase activity leads to aberrant patterns of
phosphorylation. Dysregulated phosphorylation/dephos-
phorylation underlies numerous human diseases, including
but not restricted to diabetes [5], cancer [6–8], autism [9],
Alzheimer’s disease [10], Lafora’s disease [11] and
Parkinson’s disease [12].
Tyrosine phosphatases
To date, 107 genes encoding tyrosine phosphatases have
been identified in the human genome [13, 14]. All share
the ability to hydrolyze p-nitrophenyl phosphate, are in-
hibited by vanadate and are insensitive to okadaic acid 
[15, 16]. In addition to their ability to dephosphorylate
phosphotyrosine residues, a subset of tyrosine phos-
phatases can also dephosphorylate phosphoserine or
phosphothreonine residues. These dual-specificity phos-
phatases may also target messenger RNA (mRNA), phos-
pholipids and phosphoinositides in addition to phospho-
proteins. Membrane-spanning phosphotyrosine-specific
phosphatases are known collectively as receptor-like
protein tyrosine phosphatases, whereas others lack mem-
brane-spanning domains and are found in the cytoplasm.
Except for the Eya (eyes absent) tyrosine phosphatases,
Table 1. Overview of potential neuroprotection conferred by Tyr and Ser/Thr protein phosphatases.
Protein phosphatase Model tested for neuroprotection (Hypothetical/proposed) neuroprotective  Ref.
mechanisms
Tyrosine phosphatases
SHP1 permanent focal cerebral ischemia reduction of glial activation [72, 73]
cochlear ablation reduction of proinflammatory cytokines/
enhancement of anti-inflammatory cytokines
SHP2 focal cerebral ischemia/reperfusion enhancement of neurotrophin signalling [67, 68]
nitric oxide toxicity
PTPa* not tested dephosphorylation and enhancement [74, 75, 78] 
of potassium channel Kv1.2 currents
* potential neurotoxic role: activation 
of Src family kinases and enhanced 
currents through NMDA receptors
STEP not tested dephosphorylation of Src family kinases [52, 55]
reduction of currents through NMDA 
receptors
PTEN* promotes glutamate excitotoxicity * increases Akt activity, [80, 82]
promotes focal ischemic damage * increases currents through NMDA 
receptors
Serine/Threonine 
phosphatases
Calcineurin (PP2B)* transient forebrain ischemia dephosphorylation of the NR2A subunit of   [86, 87]
the NMDA receptor, desensitization of NMDA   
receptor
hypoxia/aglycemia in brain slices interaction with Bcl-2, dephosphorylation [88, 89]
glutamate treatment of mouse primary of IP3-Rs   
cortical cultures nicotine-mediated inactivation of L-type [92]
calcium-channels
PP1 hypoxia in epithelial cells dephosphorylation, ubiquitination and [84] 
degradation of CREB
* Activity of these phosphatases may exacerbate neurotoxic processes.
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which use a different catalytic process requiring an aspar-
tic acid [17], dephosphorylation generally begins when a
protein with a phosphorylated tyrosine residue enters the
active site of the phosphatase. Then the phosphoryl group
is transferred to a key cysteine residue by nucleophilic 
attack, after which the tyrosine is protonated and ejected
from the active site. The thiol intermediate on the cysteine
residue is then hydrolysed, and the phosphatase is re-
turned to its resting state [18, 19].
Target specificity of tyrosine phosphatases is ensured by
multiple molecular strategies. One mechanism relies on
the property that different tyrosine phosphatases prefer-
entially recognize certain phosphopeptides. Specificity
is also achieved by cell-type and organelle-specific ex-
pression of individual PTPs (protein tyrosine phos-
phatases). In addition, most tyrosine phosphatases have
multiple domains, which may be involved in target
recognition and in localization to particular cellular
compartments and complexes of protein assemblies. For
example, SHP-1 and SHP-2 possess Src homology 2
(SH2) domains, LAR and RPTP have immunoglobulin-
and fibronectin-like domains, and the Eya members con-
tain DNA recognition sequences. The presence or exclu-
sion of particular tyrosine phosphatases in protein com-
plexes is critical for their signalling specificity. For ex-
ample, CD45, which is found in all hematopoetic cells,
can activate Src family tyrosine kinases by dephosphor-
ylating the inhibitory site or can inhibit them by dephos-
phorylating the activation site depending on the cell type.
The mechanism whereby pathway specificity is deter-
mined appears to be the co-localization of or exclusion
of CD45 from the receptor/Src signalling complex [20]. 
Serine/threonine phosphatases
Like PTPs, Ser/Thr protein phosphatases represent a di-
verse family, are expressed in many cell types and cellular
compartments, and are regulated via several mechanisms
[21, 22]. They are classified into PPP and PPM families
defined by distinct amino acid sequence and 3-dimen-
sional structure. The major phosphatases in the PPP
family are PP1, PP2A and PP2B (calcineurin), and the
PPM family includes PP2C. PP1, PP2A and PP2B are
composed of catalytic and regulatory subunits, with each
subunit type being expressed in several isoforms by dis-
tinct genes and/or alternative splicing. By contrast,
PP2C exists as a monomer devoid of regulatory subunits.
Regulatory subunits generally have multiple functions,
including controlling catalytic activity, subcellular lo-
calization and substrate-specificity of the protein phos-
phatase. The marked molecular diversity brought about
by the varied subunit composition is further enhanced by
the requirement of covalent modifications on some sub-
units and/or the dependence on specific ions. For in-
stance, PP2B requires Ca2+ and calmodulin for full ac-
tivity, whereas PP2C needs Mg2+ or Mn2+ [21, 22].
The specificity and activity of Ser/Thr protein phos-
phatases are largely controlled by interacting partners and
Figure 1. Schematic representation of pathways associated with excitotoxic events. Excessive glutamate overactivates glutamate receptors
leading to increased intracellular Ca2+ ([Ca2+i]) and the activation of multiple downstream pathways. Protein phosphatases may intervene
in several parts of these pathways to activate or inhibit different substrates. See text for more detail. NOS nitric oxide synthase, VDCC 
voltage-dependent Ca2+ channel, ASIC acid sensing ion channel, GP G protein, PLC phospholipase C.
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scaffolding proteins. These proteins act as regulatory 
subunits that compartmentalize phosphatase subunits in
discrete subcellular locations and bring them into close
proximity with target substrates [23]. They thereby con-
fer spatial control to their catalytic activity. In the brain,
localization of protein phosphatases to synaptic struc-
tures such as the postsynaptic density (PSD) is critical for
neuronal signalling. For example, the g1 subunit of PP1
is specifically concentrated in dendrites and presynaptic
boutons in part through attachment to the anchoring pro-
tein yotiao localized in these compartments. In addition
to compartmentalizing protein phosphatases, anchoring
proteins also have inhibitory or activating actions towards
different substrates. For instance, A-kinase anchoring
proteins (AKAPs) belong to a family of proteins that can
anchor PP2B and protein kinase A (PKA) to N-methyl-
D-aspartate (NMDA) receptors, and therefore control the
activity of this complex. Likewise, spinophilin is a binding
protein containing a PDZ domain (postsynaptic-density-
protein/disc-large/zo-1 domain) that mediates the associa-
tion of PP1 with actin and neurotransmitter receptors such
as the D2 dopamine (DA) receptor [24], the alpha adrener-
gic receptor [25] and p70S6 kinase (p70S6K) [26]. Other
interacting proteins have also been found to have dual
functions depending on their partner. Inhibitor 1/PP2A and
inhibitor 2/PP2A are two proteins known to inhibit PP2A
that can also stimulate PP1 activity in vitro [unlike in-
hibitor-1 (I1), which is a PP1 inhibitor] [27].
In addition to anchoring proteins, specific endogenous
activators/inhibitors exist that contribute to regulating
phosphatase activity. Their nature and mode of action
may vary depending on cell type and brain structure. I1
and dopamine and cyclic AMP (cAMP)-regulated phos-
phoprotein Mr 32000 (DARPP-32) are two PP1 inhibitors
(different from inhibitor 1/PP2A above) with similar se-
quences that are selectively expressed in cortical/hippo-
campal neurons or striatal neurons, respectively. Finally,
phosphatase activity can be controlled by redox mecha-
nisms such as demonstrated for PP2B. Overall, these mul-
tiple mechanisms represent an intricate means of tightly
regulating the activity, substrate specificity and intracel-
lular localization of protein phosphatases, making them
highly selective.
The role of protein phosphatases in the cascade of events
triggered during excitotoxic cell death has not been ex-
tensively studied, but some protein phosphatases, such as
Ca2+-dependent calcineurin, were found to contribute to
excitotoxicity (because its inhibition is neuroprotective
[28]). However, recent findings have indicated that pro-
tein phosphatases are implicated in both excitotoxic and
cell survival mechanisms, depending on the timing of
their activation, the nature and extent of the insult etc.
These findings have prompted interest in studying their
role as endogenous neuroprotective molecules and, in
turn, considering their use as potential drug targets for 
the treatment of disorders involving excitotoxicity and
neuronal cell death [8, 29, 30].
Events underlying excitotoxicity 
Excitotoxicity is a complex process initiated when neu-
ronal receptors for excitatory neurotransmitters are ex-
cessively activated during traumatic events such as cere-
bral ischemia, brain injury or seizure [31, 32]. Since sev-
eral of the protein phosphatases discussed here might be
neuroprotective by decreasing processes leading to exci-
totoxic cell death, the main aspects of this process will 
be reviewed. Excitotoxicity is triggered by energy and
oxygen deprivation, and disruption of ionic homeostasis
[33]. Under these deleterious conditions, neurons
strongly depolarize, which leads to an excessive entry of
calcium through calcium-permeant channels such as volt-
age-dependent calcium channels, channels associated
with ionotropic glutamate receptors such as the NMDA
receptor [34], transient receptor potential channels [35]
and acid-sensing channels [36]. The NMDA receptor is
recognized as one of the major mediators of calcium in-
flux, triggering excitotoxic cell death in numerous neuro-
logical disorders [1, 37, 38]. As following hypoxia [39],
oxygen-glucose deprivation enhances currents through
NMDA receptors in hippocampal CA1 pyramidal neu-
rons, but this does not occur in CA3 pyramidal neurons
[P. Benquet, C. E. Gee and U. Gerber, unpublished obser-
vations]. Transient forebrain ischemia also increases
NMDA receptor currents in CA1, leading to selective cell
death of these neurons [40]. NMDA receptors are regu-
lated by protein phosphorylation and are thus a central
target of kinases and phosphatases during both excitotox-
icity and cell survival [41]. Further to extracellular cal-
cium entry, calcium release from endoplasmic reticulum
stores contributes to massively increasing the level 
of intracellular calcium during excitotoxicity. Excessive
activation of 1,4,5-inositol-trisphosphate receptors 
(IP3-Rs) by IP3 leads to depletion of these Ca2+ stores and
triggers neuronal death through both necrosis and apop-
tosis [42].
In addition to calcium entry, the production of reactive
oxygen species exacerbates excitotoxic cell damage [32,
38], possibly by enhancing the activity of protein kinases
or decreasing the activity of protein phosphatases [43].
The NMDA receptor is closely linked to the neuronal en-
zyme nitric oxide synthase (NOS) via PSD-95 interac-
tions. Calcium entering through NMDA receptors stimu-
lates NO production by NOS, which is neurotoxic at high
levels [44, 45]. This observation may explain why calcium
entering through NMDA receptors is more neurotoxic
than calcium entering through voltage-dependent calcium
channels or non-NMDA ionotropic glutamate receptors
[46].
1124 C. E. Gee and I. M. Mansuy Protein phosphatases in neuroprotective processes
The induction of ischemic insult is accompanied by an
impairment of mitochondrial functions, a decrease in the
concentration of ATP and glucose, an accumulation of
lactate and often also the initiation of inflammatory re-
sponses. Neurons within the injury core may then un-
dergo apoptotic cell death or die as a result of necrosis
[33]. A substantial number of neurons in regions adjacent
to the injury core (the penumbra) may also be affected
and die by programmed cell death, which contributes to a
significant loss of neurological functions. Nevertheless,
the viability of neurons in the penumbra is generally bet-
ter than in the core, and therefore these neurons have a
higher potential for preservation by appropriate interven-
tion. Importantly, the occurrence of an excitotoxic event
is accompanied by the activation of endogenous cell sur-
vival pathways that counteract cell death pathways. 
Mechanistically, excitotoxic events engage many of the
intracellular molecules that mediate neuronal signalling
in physiological conditions. These molecules intervene in
two different ways: either they contribute to damage and
promote neuronal death, or they counteract damage and
sustain cell survival. Clearly, several individual mole-
cules can take part in both processes depending on the
type and level of injury, the homeostatic state of the in-
jured cell and the timing after injury. Tyrosine and
Ser/Thr protein phosphatases in particular play an active
role in both processes and can have excitotoxic and neu-
roprotective functions. For instance, dramatic changes 
in phosphorylation/dephosphorylation of many proteins
have been demonstrated during global ischemia and sub-
sequent brain reperfusion. We will focus in the following
section primarily on protein phosphatases with potential
neuroprotective functions.
Protein phosphatases that may be neuroprotective
Tyrosine phosphatases
Several protein phosphatases have been found to take part
in processes that counteract excitotoxic or other insults and
therefore may function as neuroprotectants. Possible neu-
roprotective candidates include the tyrosine phosphatases
striatal-enriched phosphatase (STEP), the SH2-containing
tyrosine phosphatases SHP1, SHP2 and protein tyrosine
phosphatase alpha (PTPa). PTPa may also promote neu-
rotoxicity as has been shown for the tyrosine phosphatase
phosphatase and tensin homolog deleted from chromo-
some 10 (PTEN). In trauma or disorders such as cerebral
ischemia [47, 48], epileptiform activity [49, 50] or Alz-
heimer’s disease [51], increased tyrosine phosphorylation
mediated by Src or Fyn kinases is suggested to promote
neuronal cell death.
Endogenous pathways and mechanisms involving protein
phosphatases have evolved to counteract the negative ef-
fects of hyperphosphorylation. Because of its association
with the NMDA receptor complex, the tyrosine phos-
phatase STEP, especially its large isoform STEP61, is
poised to fulfill such a function by opposing the potenti-
ating effects of Src family kinase phosphorylation on
NMDA receptor function [52]. In spite of its name, STEP
is expressed in many regions of the brain, including the
basal ganglia, striatum, cortex and hippocampus. It is
composed of four isoforms, a large membrane-bound
form (STEP61) and three lower molecular weight cytoso-
lic isoforms [53]. Following transient global ischemia,
STEP immunoreactivity increases in glia, specifically in
regions where neurons undergo cell death [54]. In neu-
rons, STEP dephosphorylates and inactivates several tar-
gets, including the Src family kinase Fyn [55] and ERK
(extracellular signal-related kinase) [56]. These targets of
STEP have also been implicated in neuronal death. Dur-
ing forebrain hypoxia/ischemia, STEP61 is cleaved and its
catalytic domain is released into the cytosol as a small
molecular weight isoform (STEP33) [57]. It is not clear
whether STEP33 maintains its catalytic activity and
whether its separation from the NMDA receptor complex
changes its availability; however, STEP appears to be a
good candidate for reversing Src-dependent enhancement
of NMDA currents. It is possible that its cleavage is pre-
vented in ischemia-resistant neurons and may contribute
to the tyrosine phosphatase-dependent maintenance of
NMDA currents in protected CA3 cells. Interestingly,
STEP is activated by dephosphorylation by the calcium-
dependent Ser/Thr protein phosphatase calcineurin [56],
which is more abundant in CA3 neurons, and therefore
STEP may be part of a complex mechanism counteract-
ing Src-dependent enhancement of NMDA responses
[52].
Besides STEP, several other protein phosphatases also
control Src activity and Src-mediated phosphorylation of
targets involved in excitotoxicity. Src activation depends
on the phosphorylation/dephosphorylation of two tyrosine
residues, Y527 and Y416, with Y527 phosphorylation be-
ing inhibitory and Y416 phosphorylation being excitatory.
The tyrosine phosphatases SHP2 and PTPa increase Src
activity by promoting Y527 dephosphorylation either in-
directly for SHP2 by reducing the interaction of Src with
the tyrosine kinase Csk [58] or directly for PTPa [59]. De-
spite this function, however, SHP2 was found to promote
cell survival by mechanisms that are not well understood
but that may involve enhancement of neurotrophin sig-
nalling [60–62]. SHP2 is expressed in various neurons in
human and mouse adult brain [63, 64] and is localized in
pre- and postsynaptic membranes [65] and mitochondria
[66]. It is essential during development and its loss by
knockout is lethal. Its downregulation, achieved by expres-
sion of a dominant negative in the adult brain, increases the
sensitivity to focal cerebral ischemia/reperfusion injury
[67]. Consistently, in a model of CNS injury using nitric
oxide, SHP2 inhibition was found to reduce survival of
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primary cultured neurons and increase caspase activation,
a marker of programmed cell death [68]. It may have a
neuroprotective role as its level of activity increases in 
reactive glia following permanent focal ischemia [64].
The targets of SHP2 have not all been identified, but 
tyrosine kinase-dependent signalling pathways are posi-
tively regulated by SHP2 through, for instance, dephos-
phorylation and inactivation of the receptor tyrosine ki-
nase inhibitor Sprouty [69]. SHP2 itself is also activated
by tyrosine phosphorylation [70] and therefore appears as
a central component of feedback and crosstalk mecha-
nisms between multiple signalling pathways.
SHP1 is a tyrosine phosphatase with SH2 domains that is
upregulated in rodent brain following insult. SHP1 is
found in some neurons but is primarily expressed in glial
cells such that loss of SHP1 leads to dysmyelination in the
central nervous system (CNS) [71]. In young mice, SHP1
is upregulated by permanent focal cerebral ischemia in
non-dividing astrocytes and microglia and appears to limit
their activation, thereby reducing the potential for glial
scar formation [72]. The production of some anti- and pro-
inflammatory cytokines following deafferentation is also
decreased and increased, respectively, in SHP1 mutants,
suggesting that a further neuroprotective action of SHP1
is the reduction of the inflammatory response triggered
by glial activation [73].
PTPa activity regulates the activity of neuronal Kv1.2
potassium channels and NMDA receptors. Carbachol ac-
tivates m1 muscarinic receptors, resulting in tyrosine
phosphorylation that correlates with the suppression of
Kv1.2 channel currents [74]. PTPa activity is increased
by carbachol via tyrosine phosphorylation. Carbachol
stimulation additionally promotes the association of phos-
phorylated PTPa with phosphorylated Kv1.2 channels,
resulting in dephosphorylation, which reverses the sup-
pression of currents [75]. Increasing conductance of
potassium channels to hyperpolarize neurons is an impor-
tant mechanism to limit calcium entry during excitotoxic-
ity. Whether PTPa activity plays a role in maintaining
potassium channel activity under excitotoxic conditions
has not been explored. However, it is known that oxida-
tive stress promotes a conformational change in PTPa
dimers that reduces its activity and would be maladaptive
in this context [76, 77]. Another effect of PTPa activity is
to activate Src family kinases and increase currents
through NMDA receptors [78]. An increase in this prop-
erty of PTPa during insults would be expected to exacer-
bate injury; thus it is unclear whether promoting PTPa
activity would be neuroprotective or whether the reduc-
tion of PTPa activity by reactive oxygen species would
instead be neuroprotective.
PTEN is a dual-specificity kinase that dephosphorylates
phosphotyrosine and phosphoserine/threonine-contain-
ing substrates [79]. In contrast to most of the other phos-
phatases mentioned in this review, downregulation of
PTEN is neuroprotective against glutamate excitotox-
icity [80] and transient focal ischemia [81]. PTEN inter-
acts with NR1/NR2B-containing NMDA receptors [82].
Knock-down of PTEN with small interfering RNA
(siRNA) decreases currents through the extrasynaptic
NR1/NR2B-containing NMDA receptors by decreasing
both the channel-open probability and the surface expres-
sion of the channels. Neuroprotection against transient
global ischemia-induced neuronal death conferred by
PTEN downregulation depends on the resulting increase
in Akt activity and the decrease in NMDA receptor cur-
rents [82].
Ser/Thr phosphatases
In parallel to Tyr protein kinases and protein phos-
phatases, numerous Ser/Thr kinases and phosphatases are
activated during excitotoxic and cell survival events and
participate in controlling the outcome of insults to the
brain. Protein kinases such as the Ca2+/calmodulin-de-
pendent protein kinase CaMKII, protein kinase C (PKC)
and A (PKA), and Cdk5 are recruited. For instance, phos-
phorylation by Cdk5 is activated in CA1 hippocampal
neurons after transient forebrain ischemia and targets, in
particular, the NR2A subunit of the NMDA receptor [40].
Such phosphorylation is detrimental to tissue because its
prevention by inhibition of endogenous Cdk5 or by block-
ade of its interaction with NR2A protects CA1 pyramidal
neurons from ischemic insult. This mechanism may con-
tribute to the selective vulnerability of CA1 neurons to 
ischemia. Concomitantly to kinases, several Ser/Thr pro-
tein phosphatases, such as PP1, calcineurin and PP2A are
activated to counteract the effect of kinases. In the rat 
hippocampus in vivo, inhibition of PP1 by okadaic acid
increases NMDA receptor phosphorylation and induces a
marked degeneration of CA1 hippocampal neurons, sug-
gesting a positive effect of PP1 on cell survival [83].
Likewise, in vitro, PP1 inhibition mimics the physiologi-
cal effects of hypoxia and severe hypoxia in epithelial cell
culture and is accompanied by downregulation of PP1g
expression. The drop in PP1 leads to hyperphosphoryla-
tion of several PP1 targets, including the transcription
factor CREB [84], followed by ubiquitination and pro-
teosomal degradation of CREB, a final phase in the ex-
pression of hypoxic damage. During ischemia, PP1 may
also control the formation of clusters of CaMKII in synap-
tic terminals, which represents a cellular strategy to pre-
vent CaMKII-mediated phosphorylation during episodes
of Ca2+ overload [85].
Despite its recognized role as a major mediator of exci-
totoxicity and neuronal cell death, calcineurin is also in-
volved in mechanisms of neuroprotection [86]. Following
transient forebrain ischemia, calcineurin activity de-
creases in the hippocampus, but interestingly not to the
same extent in CA1 and CA3 neurons. While it decreases
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only transiently in the CA3 region, it does so persistently
in CA1 neurons. This may result from its larger concen-
tration in CA3 versus CA1 neurons under normal condi-
tions, a difference that may maintain homeostatic levels of
NMDA receptor phosphorylation. It may also help reverse
ischemia-induced NMDA hyperactivation to prevent exci-
totoxicity. Calcineurin can efficiently downregulate
NMDA receptor activity by dephosphorylating NR2A and
desensitizing the receptor, a mechanism known to be neu-
roprotective [87]. It can also inactivate L-type Ca2+ chan-
nels and thereby diminish Ca2+ entry [21, 22].
Another target of calcineurin involved in neuroprotection
is Bcl-2, a critical regulator of apoptosis. During the early
phase of hypoxia/aglycia in brain slices, calcineurin and
Bcl-2 interact, and this interaction triggers the shuttling of
calcineurin to intracellular substrates, in particular the 
IP3-Rs [88, 89]. Shuttling of cellular proteins to their sub-
strates by Bcl-2 is actually a general anti-apoptotic mech-
anism [90]. By dephosphorylating IP3-Rs, calcineurin in-
hibits excitation-induced calcium release from internal
stores, thereby preventing further increase in calcium in
the cell and the depletion of calcium stores [91]. Cal-
cineurin-induced desensitization of IP3-Rs may be an im-
portant neuronal defense system against excitotoxicity.
Calcineurin is involved in specific mechanisms of neuro-
protection such as those induced by nicotine. Nicotine
pretreatment is effective in reducing cell death in cortical
neurons subjected to glutamate overactivation. This pro-
tective function is mediated by activation of  alpha7- and
beta2-containing nicotinic acetylcholine receptors fol-
lowed by Ca2+ influx and recruitment of calcineurin [92].
Nicotine-mediated effects are abolished when cal-
cineurin is inhibited before glutamate excitotoxicity.
However, when inhibited only after glutamate overload,
the neurons are preserved. This observation is consistent
with the demonstrated neuroprotective effect of the inhi-
bition of calcineurin by immunosuppressants such as cy-
closporin A and FK506 [86]. It illustrates the dual role of
calcineurin in excitotoxic cell death, depending on
whether it is activated or inhibited, and whether this oc-
curs before, during or after insult. Thus, calcineurin acti-
vation before excitotoxicity is neuroprotective, whereas
its activation after excitotoxicity promotes damage, in
which case calcineurin blockade is neuroprotective. This
duality is reminiscent of the binary nature of the activa-
tion of the NMDA receptor itself that, depending on its
level, either mediates excitotoxic cell death or promotes
activity-dependent cell survival. Thus, strong NMDA re-
ceptor activation by high concentrations of NMDA in-
duces excitotoxicity accompanied by calcineurin activa-
tion and transient increase in the phosphorylation of the
transcription factor CREB. By contrast, non-toxic levels
of NMDA mimic endogenous synaptic activity without
activating calcineurin but with sustained CREB phospho-
rylation [93]. The mechanisms and targets involved in
calcineurin signalling during excitotoxic/neuroprotective
events are thus variable, depending on the nature and ex-
tent of the injury, the temporal stage, the affected brain
area and the cell type.
Finally, the apparent discrepancy between the demon-
strated neuroprotective property of calcineurin inhibitors
such as the immunosuppressants CsA and FK506, and the
potential neuroprotective function of calcineurin itself,
may be accounted for by indirect mechanisms of drug ac-
tion. For instance, CsA acts through inhibition of the im-
munophilin cyclophilin D, which itself can prevent mito-
chondrial damage [94]. Also FK506, in addition to inhibit-
ing calcineurin, activates heat shock proteins and is
therefore not specific [95]. Another possible mechanism of
immunosuppressant-mediated neuroprotection may be via
inhibition of astrocyte and microglial activation and prolif-
eration, and reduction of the inflammatory response [28].
Search for endogenous mechanisms 
of neuroprotection
As CA1 pyramidal neurons are more sensitive to excito-
toxic injury than CA3 pyramidal neurons, it is of interest
to exploit this property to study the mechanisms underly-
ing excitotoxicity and endogenous neuroprotective mech-
anisms. In an attempt to identify the molecular targets 
potentially involved in such mechanisms, a recent study
compared the profile of gene expression in microdis-
sected human CA1 versus CA3 pyramidal neurons. At
least 60 genes were found to be differentially expressed 
at the mRNA level in these neurons (a minimum 1.7-fold
enrichment) [96]. Among them, two Ser/Thr kinases,
JNK and JNK2, involved in apoptotic cell death were
more highly expressed in CA1 pyramidal neurons. Block-
ade of JNK activation after cerebral ischemia was found
to be neuroprotective, suggesting that JNK promotes exci-
totoxicity [97, 98], which is consistent with the increased
level of JNK expression observed after ischemia [99,
100]. However, this increase may be counteracted by pro-
tein phosphatases, in particular the dual-specificity pro-
tein phosphatase MKP (MAP kinase phosphatase), which
was found to dephosphorylate and inactivate JNK [101].
However, MKP activity was found to decrease with hy-
poxia. Ultimately, the net balance between this kinase/
phosphatase interplay determines whether cell death or
survival is favoured.
Another molecule more predominantly expressed in CA1
than in CA3 is the receptor-like tyrosine phosphatase 
PTPro. In brain, PTPro is highest during development,
where it is postulated to play a role in axogenesis [102,
103]. In adult brain, its levels remain high in CA1 neu-
rons and certain other cell types [104]. The function of
PTPro has not been explored in the adult brain or during
excitotoxic injury, but it may be important.
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As previously mentioned, currents through NMDA recep-
tors are enhanced in several models of ischemic insult. In
vitro oxygen-glucose deprivation rapidly enhances NMDA
currents in CA1 pyramidal neurons, but not in the less vul-
nerable CA3 pyramidal neurons [P. Benquet, C. E. Gee
and U. Gerber, unpublished observations]. In CA3 pyra-
midal neurons, inhibiting tyrosine phosphatases unmasks
a similar tyrosine kinase-dependent enhancement of
NMDA currents and exacerbates ensuing cell death, sug-
gesting that tyrosine phosphatase activity contributes to
protection of these neurons. Whether enhancing this phos-
phatase activity in more vulnerable neurons will be neuro-
protective warrants further investigation.
Conclusions and perspectives
At present the possible role of protein phosphatases in 
either preventing or promoting excitotoxic mechanisms 
is not fully understood. As their modes of action are com-
plex, their effects may be diametrically opposed, depend-
ing on the type and extent of injury, the area of the brain
and cell type injured, and the physiological state of the
cell. Concerted efforts will be required to elucidate the
mechanisms through which they act. In addition to the 
excitatory mechanisms delineated above, non-excitatory
processes may also mediate glutamate excitotoxicity and
cell death, as recently shown in retinal ganglion cells
[105]. These mechanisms involve kainate-type ionotropic
glutamate receptors and calcium influx but no depo-
larization. Protein phosphatases are also implicated in 
these processes. For instance, cellular damage induced by
kainate is reduced by the calcineurin inhibitor CsA. How-
ever, here again little is known about the mechanisms 
involved. Thus, overall, better knowledge of the mecha-
nisms of excitotoxicity will be indispensable in develop-
ing new approaches for the treatment of brain trauma and
disorders associated with neuronal cell death, and should 
allow the design of novel neuroprotective agents [106].
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